QNASL Approval History

• FDA approved: Yes (First approved March 23rd, 2012)
• Brand name: QNASL
• Generic name: beclomethasone dipropionate
• Company: Teva Pharmaceutical Industries Ltd.
• Treatment for: Hay Fever

QNASL (beclomethasone dipropionate) is an intranasal corticosteroid non-aqueous "dry" spray formulation for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

FDA Approval History for QNASL

Date	Article
Mar 26, 2012	Teva Announces FDA Approval of QNASL (beclomethasone dipropionate), a New Nonaqueous Nasal Aerosol, for the Treatment of Allergic Rhinitis
Aug  8, 2011	Teva Receives FDA Acceptance of Its New Drug Application for BDP Nasal HFA for the Treatment of Allergic Rhinitis

See also...

QNASL (beclomethasone dipropionate) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.